POINT Biopharma Announces Publication of Dosimetry Summary

Dosimetry data demonstrated that PNT2002 has a favorable and safe dosimetry profile in the patient population and study regimen

Red marrow dosimetry was well below critical thresholds, allowing a potential opportunity for combination therapy

INDIANAPOLIS, Feb. 25 08, 2022 (GLOBE NEWSWIRE) — POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development and global access to life-changing radiopharmaceuticals , today announced the publication of initial cohort 27-patient safety and dosimetry data for the company’s Phase 3 SPLASH trial (NCT04647526) evaluating PNT2002 for the treatment of resistant metastatic prostate cancer. Castration (mCRPC) at the SNMMI Mid-2022 Annual Winter Meeting and the ACNM, February 25-27, 2022.

“We are encouraged by the favorable red marrow dosimetry which highlights the potential opportunity of PNT2002 as a combination therapy in advanced prostate cancer.” said Dr. Neil Fleshner, Medical Director of POINT Biopharma. “While radioligand therapies have historically shown promise as monotherapy, we look forward to evaluating whether better clinical and patient outcomes can result from a combined treatment approach.”

Data from the abstract titled “Dosimetry Results from the SPLASH Trial” (Abstract #: MWMA2244) demonstrated the following:

For a cumulative administered activity of 27.2 GBq, i.e. four cycles of 6.8 GBq, the kidneys would receive a cumulative absorbed dose of 19.9 Gy, and the red marrow a cumulative absorbed dose of 0.91 Gy.

The organs receiving the highest absorbed doses were the lacrimal glands at 1.2 Gy/GBq, followed by the kidneys at 0.73 Gy/GBq.

The mean dose to salivary glands and red marrow was 0.34 Gy/GBq and 0.034 Gy/GBq, respectively.

SPECT/CT versus planar renal dosimetry was consistent in most subjects (± 20%) for whom SPECT/CT images were available with a mean kidney absorbed dose difference of 1%.

“These results represent an important milestone for the PNT2002 clinical program.” said Dr. Joe McCann, CEO of POINT Biopharma “The dosimetry data generated in the SPLASH introduction validates the published literature and the comprehensive approach that POINT has leveraged to accelerate the clinical development program.”

Radiation dosimetry of PNT2002 was calculated in ​27 patients with mCRPC based on whole body planar conjugate imaging biodistribution data at 1, 24, 48, 72 and 168 hours and, for 7 of them, SPECT/CT imaging at 48-72 hours after the injection of their first cycle of PNT2002 (6.8±10% GBq).

The Phase 3 SPLASH trial is a multicenter, randomized, open-label evaluation of PNT2002 in patients with avid mCRPC PSMA who progressed after treatment with androgen receptor axis-targeted therapy (ARAT). The treatment regimen of the initial cohort is the same as that studied in the randomization part of the trial. The randomization phase of SPLASH is currently recruiting approximately 400 patients in the United States, Canada and Europe. There are 25 sites currently registering in North America. Site activations across Europe and the UK are underway.

Patients will be randomized 2:1 with Arm A patients receiving PNT2002 and Arm B patients receiving either abiraterone or enzalutamide with licensed supportive medications. Patients in Arm B who have centrally assessed radiographic progression and meet protocol eligibility criteria will be offered the option to proceed to and receive PNT2002. Patients will be followed for up to 5 years from the first dose of PNT2002. The primary endpoint of the study is radiographic progression-free survival (rPFS). Key secondary endpoints include overall response rate (ORR), overall survival (OS), and pharmacokinetics (PK). The company expects to release key SPLASH data in mid-2023.

A copy of the poster will be available under the Presentations tab of the Investors section of the Company’s website at https://www.pointbiopharma.com/.

About POINT Biopharma Global Inc.
POINT Biopharma Global Inc. is a global radiopharmaceutical company building a platform for the clinical development and commercialization of cancer-fighting radioligands. POINT is transforming precision medicine by combining a portfolio of best-in-class radiopharmaceutical assets, a seasoned management team, a state-of-the-art pipeline, in-house manufacturing capabilities and a secure supply of rare medical isotopes like actinium-225 and lutetium -177. Learn more about POINT Biopharma Global Inc. at https://www.pointbiopharma.com/. Information about POINT Biopharma Global Inc.’s Phase 3 SPLASH trial for patients with metastatic castration-resistant prostate cancer (mCRPC) is available at https://www.splashtrial.com/.

Forward-looking statements

This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. In some instances, you may identify forward-looking statements by the following words: “may”, “will, ” “could”, “do”, “should”, “expect”, “intend”, “plan”, “anticipate”, “believe”, “estimate”, “predict”, “project “, “potential”, “continuing”, “ongoing” or the negative form of these terms or other comparable terms, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to differ materially from the information expressed or implied by such forward-looking statements. Although we believe we have a reasonable basis for each statement prospective contained in this press release We caution you that these statements are based on a combination of facts and factors currently known to us and our projections for the future, about which we cannot be certain. Forward-looking statements in this press release include, but are not limited to, statements regarding the benefits of the recently completed business combination, as well as statements about the attributes and potential benefits of POINT’s product candidates and the format and POINT’s product development schedule. clinical activities and trials. We cannot assure you that the forward-looking statements contained in this press release will prove to be accurate. These forward-looking statements are subject to a number of important risks and uncertainties that could cause actual results to differ materially from expected results, including, among other things, the outcome of any legal proceedings that may be brought against POINT after closing the business. combination, the risk that the business combination will disrupt ongoing plans and operations, the ability to recognize the anticipated benefits of the business combination, which may be affected by, among other things, competition, POINT’s ability to grow and to manage growth profitably and retain its key employees, the impact of COVID-19 on POINT’s business, the ability to maintain the listing of POINT’s common stock on NASDAQ, changes in applicable laws or regulations, the possibility that POINT may be affected by other economic, business and/or competitive factors, and other risks and uncertainties, including those described in POINT’s S-1 Registration Statement File ed with the SEC on July 30, 2021. Most of these factors are beyond POINT’s control and are difficult to predict. In addition, if the forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the material uncertainties in these forward-looking statements, you should not consider these statements to be a representation or warranty by us or anyone else that we will achieve our goals and plans within a specified time frame, or at all. The forward-looking statements contained in this press release represent our opinions as of the date of this press release. We anticipate that subsequent events and developments will cause our views to change. However, while we may choose to update these forward-looking statements at some time in the future, we currently have no intention of doing so except as required by applicable law. You should therefore not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this press release.

Ari Shomair
[email protected]
(317) 543-9957

Contact with Investor Relations:
Alex Lobo
Serious investor relations
[email protected]

Jacob L. Thornton